Catalyst Wire Dossier Catalyst Wire Dossier

DE-109 sirolimus

sirolimus · Santen Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for DE-109 sirolimus, covering 2023-12-04 to 2023-12-04. Get the full timeline:

Most recent: Clinical Trial Update: LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye [Phase 3]

See pricing